 | ||||||
| Currency | ||||||
| NEWS | ||||||
| Currency and pricing squeeze GSK as new shingles vaccine shines Elsewhere, the going remains tough for GSK's business, with the full-year earnings hit from currency moves now seen at 8 percent, against 6 percent previously. And GSK expects more sales erosion for its ageing lung inhaler Advair in the key U.S. market - even before generic rivals are launched - due ...
| ||||||
| See more results | Edit this alert | ||||||
| You have received this email because you have subscribed to Google Alerts. |
 Receive this alert as RSS feed |
| Send Feedback |
